Insmed Announces Addition of Top 25 Patent Lawyer to Litigation Team
24 Octobre 2006 - 2:15PM
Business Wire
Insmed Incorporated (Nasdaq: INSM) announced today the addition of
Henry Bunsow as outside counsel to its legal team. Mr. Bunsow was
recently named one of the top 25 patent attorneys in California.
Henry Bunsow is the Managing Partner of the Northern California
offices of Howrey Simon Arnold & White, LLP. As Managing
Partner, Mr. Bunsow has represented clients before district courts
and courts of appeal in intellectual property cases involving
various technologies. Joining Mr. Bunsow on Insmed�s litigation
team are David Bilsker, and Rick Chang. With over 30 years
experience in intellectual property litigation, Mr. Bunsow has
tried over 30 cases to verdict or judgment with a 90% win-rate. He
has successfully argued numerous appeals before the Court of
Appeals for the Federal Circuit. During 2001-2004, he tried and won
six jury patent cases, four for the patent owner and two
representing the accused infringer. In October of 2002, Mr. Bunsow
won one of the top ten intellectual property verdicts that year
against Ericsson for infringement of a patent on wireless
communications for over $60 million, and a finding of willful
infringement. �We are very pleased to add Henry and his colleagues
at Howrey to our existing litigation team and believe they bring a
wealth of experience,� stated Geoffrey Allan, Ph.D., President and
CEO. About Insmed Insmed is a biopharmaceutical company focused on
the development and commercialization of drugs for the treatment of
metabolic diseases and endocrine disorders with unmet medical
needs. For more information, please visit www.insmed.com. Forward
Looking Statements Statements included within this press release,
which are not historical in nature, may constitute forward-looking
statements for the purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements regarding the pending litigation and or future ability
to conduct our business as now conducted and as it is currently
proposed to be conducted. Such forward-looking statements are
subject to numerous risks and uncertainties, including but not
limited to the uncertainty of the outcome of any litigation with
Tercica, the risk that product candidates may fail in the clinic or
may not be successfully marketed or manufactured, the company may
lack financial resources to complete development of product
candidates or the FDA or other regulatory agencies may interpret
the results of our studies differently than we have. We can give no
assurances that we would be successful in any litigation or that
such litigation would not have a material adverse effect on our
business, financial condition and results of operation.
Furthermore, we may not be able to afford the expense of defending
against such a claim. As a result of these and other risks and
uncertainties, actual results may differ materially from those
described in this press release. For further information with
respect to factors that could cause actual results to differ from
expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities
Exchange Act of 1934, as amended. Insmed Incorporated (Nasdaq:
INSM) announced today the addition of Henry Bunsow as outside
counsel to its legal team. Mr. Bunsow was recently named one of the
top 25 patent attorneys in California. Henry Bunsow is the Managing
Partner of the Northern California offices of Howrey Simon Arnold
& White, LLP. As Managing Partner, Mr. Bunsow has represented
clients before district courts and courts of appeal in intellectual
property cases involving various technologies. Joining Mr. Bunsow
on Insmed's litigation team are David Bilsker, and Rick Chang. With
over 30 years experience in intellectual property litigation, Mr.
Bunsow has tried over 30 cases to verdict or judgment with a 90%
win-rate. He has successfully argued numerous appeals before the
Court of Appeals for the Federal Circuit. During 2001-2004, he
tried and won six jury patent cases, four for the patent owner and
two representing the accused infringer. In October of 2002, Mr.
Bunsow won one of the top ten intellectual property verdicts that
year against Ericsson for infringement of a patent on wireless
communications for over $60 million, and a finding of willful
infringement. "We are very pleased to add Henry and his colleagues
at Howrey to our existing litigation team and believe they bring a
wealth of experience," stated Geoffrey Allan, Ph.D., President and
CEO. About Insmed Insmed is a biopharmaceutical company focused on
the development and commercialization of drugs for the treatment of
metabolic diseases and endocrine disorders with unmet medical
needs. For more information, please visit www.insmed.com. Forward
Looking Statements Statements included within this press release,
which are not historical in nature, may constitute forward-looking
statements for the purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements regarding the pending litigation and or future ability
to conduct our business as now conducted and as it is currently
proposed to be conducted. Such forward-looking statements are
subject to numerous risks and uncertainties, including but not
limited to the uncertainty of the outcome of any litigation with
Tercica, the risk that product candidates may fail in the clinic or
may not be successfully marketed or manufactured, the company may
lack financial resources to complete development of product
candidates or the FDA or other regulatory agencies may interpret
the results of our studies differently than we have. We can give no
assurances that we would be successful in any litigation or that
such litigation would not have a material adverse effect on our
business, financial condition and results of operation.
Furthermore, we may not be able to afford the expense of defending
against such a claim. As a result of these and other risks and
uncertainties, actual results may differ materially from those
described in this press release. For further information with
respect to factors that could cause actual results to differ from
expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities
Exchange Act of 1934, as amended.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024